BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$54.80
arrow_downward
-0.17%(-0.095) 1D
Oct 9, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$54.80
High
$55.98
Low
$54.48
Mkt. cap
10.61B
Avg. vol.
2.07M
Volume
0.00
P/E ratio
147.72
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
Open
$54.80
High
$55.98
Low
$54.48
Mkt. cap
10.61B
Avg. vol.
2.07M
Volume
0.00
P/E ratio
147.72
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.22
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
The Globe and Mail
·
1 day ago
Bank of America Securities Sticks to Its Buy Rating for BioMarin Pharmaceutical (BMRN)
TipRanks
·
2 days ago
BioMarin Stock Slips As Pipeline Hype Fails To Impress
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com